Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
58 trial participants mistakenly received a placebo instead of the test drug for part of the BENEFIT-ALS clinical trial of tirasemtiv in ALS
Posted on Monday, July 8, 2013 - 04:35, By: Amy Madsen
Update (Dec. 12, 2013): Cytokinetics announced in a Dec. 8, 2013, press release, that the BENEFIT-ALS trial is now fully enrolled and includes 711 participants. Lead investigator Jeremy Shefner presented a discussion of this study at the 24th International Symposium on ALS/MND, held in Milan,...
Posted on Wednesday, May 1, 2013 - 09:23, By: Amy Madsen
Name: Tirasemtiv (CK-2017357)
How it works: Tirasemtiv, developed by Cytokinetics, is designed to increase the sensitivity of muscle fibers to calcium, resulting in a potential increase in muscle force generation.
Updates on several important clinical trials were presented at an international ALS conference in December, including reports on ISIS-SOD1-Rx, NP001, neural stem cells, olesoxime and tirasemtiv
Posted on Thursday, December 13, 2012 - 16:11, By: Amy Madsen
The 23rd International Symposium on ALS/MND (motor neuron disease), held in Chicago Dec. 5-7, 2012, brought together more than 900 researchers, clinicians and other health care professionals from 30 countries to hear presentations on the latest in ALS care and research.
South San Francisco biotech Cytokinetics has opened a 400-person clinical trial to evaluate the safety, tolerability and efficacy of tirasemtiv (formerly CK-2017357) in people with ALS
Posted on Thursday, September 20, 2012 - 05:00, By: Amy Madsen
Update (Dec. 30, 2013): According to a Dec. 3, 2013, press release from Cytokinetics, this trial is closed to new participants. More than 700 patients have enrolled, and results are expected in the first half of 2014.
News about the C9ORF72 gene, National ALS Registry and Cytokinetics' experimental drug was reported at the 2012 American Academy of Neurology meeting
Posted on Friday, April 27, 2012 - 10:49, By: Amy Madsen
Among the reports given at the 2012 annual meeting of the American Academy of Neurology, being held April 21-28 in New Orleans, was information about research into amyotrophic lateral sclerosis (ALS).
Trial participants receiving the highest dose of CK-2017357 showed symptom improvement in the first stage of an ongoing phase 2 trial of this experimental drug
Posted on Tuesday, December 13, 2011 - 12:15, By: Amy Madsen
In the first stage of an ongoing phase 2 clinical trial to test the experimental therapy CK-2017357 in amyotrophic lateral sclerosis (ALS), the drug was found to be safe and well-tolerated.
Participants who received the highest dose showed improved scores on tests that measure motor and breathing...
Biotechnology company Cytokinetics has opened enrollment for a phase 2 clinical trial to study its experimental treatment CK-2017357 in ALS
Posted on Friday, July 1, 2011 - 14:34, By: Amy Madsen
San Francisco biotechnology company Cytokinetics announced June 21, 2011, that it has opened enrollment for a new clinical trial of CK-2017357 at three different dosage levels in people with ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).